Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Encompass Health

Option Care Health

RadNet

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and RDNT are well-poised to gain.

4 Stocks to Buy in a Booming Outpatient Home Health Industry

McDonald's

U.S. Steel (NYSE: X ) announced on Aug. 13 that it was undertaking a strategic review to maximize shareholder value. Once the country's largest steelmaker, it was removed as a constituent of S&P 500 stocks in June 2014.

Change of Ownership? 3 S&P 500 Giants That Should Consider Selling

Chevron

D.R. Horton

Johnson & Johnson

Kraft Heinz

Kroger

Occidental Petroleum

During times of market volatility, many investors look to see which stocks Warren Buffett is buying. Spoiler alert, you won't find him chasing the hottest AI stocks.

7 Very Oversold Warren Buffett Stocks to Buy Right Now

DaVita HealthCare (DVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

DaVita HealthCare (DVA) Upgraded to Buy: What Does It Mean for the Stock?

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

3 Reasons to Retain DaVita (DVA) Stock to Your Portfolio

DaVita Inc ( DVA , Financial), a leading player in the Healthcare Providers & Services industry, is currently trading at $115.08 with a market capitalization of $10.51 billion. The stock has seen a gain of 5.76% today and a 10.26% increase over the past four weeks.

DaVita Inc: A Healthcare Provider with Good Outperformance Potential

The shares of dialysis machine maker DaVita Inc (NYSE:DVA) are 6.6% higher to trade at $115.36 this morning, and earlier hit an 18-month high of $116.52.

Contrarian Bull Note Boosts Dialysis Stock

DaVita Inc ( DVA , Financial), a leading player in the Healthcare Providers & Services industry, is currently trading at $108.76 with a market capitalization of $9.86 billion. The stock has seen a gain of 7.09% today and an impressive 8.15% over the past four weeks.

DaVita Inc: A Healthcare Stock with Good Outperformance Potential

DaVita's (DVA) robust dialysis patient service drives its second-quarter performance.

DaVita (DVA) Tops Q2 Earnings Estimates, Ups FY23 EPS View

DaVita Inc. (NYSE:DVA ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Nic Eliason - Group Vice President, Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Joanna Gajuk - Bank of America Andrew Mok - UBS Pito Chickering - Deutsche Bank Lisa Clive - Bernstein Operator Good evening. My name is Michelle, and I will be your conference facilitator today.

DaVita Inc. (DVA) Q2 2023 Earnings Call Transcript

DaVita HealthCare (DVA) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $2.30 per share a year ago.

DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates

DaVita Inc. DVA, -0.40% shares rose in the extended session Thursday after the dialysis center company topped Wall Street estimates, and hiked its forecast for the year. DaVita shares rose as much as 5% after hours, following a 0.4% decline in the regular session to close at $101.56.

DaVita's stock gains after hours following earnings beat, outlook hike

DENVER , Aug. 3, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2023. "Over the first half of the year, DaVita has been focused on innovation in our clinical systems and driving operational improvements throughout our organization," said Javier Rodriguez, CEO of DaVita Inc. "Our second quarter performance reflects strong traction across those initiatives, putting us on a path to deliver strong clinical outcomes and financial results for the year.

DaVita Inc. 2nd Quarter 2023 Results

Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) second quarter's top line.

DaVita (DVA) to Report Q2 Earnings: What's in the Offing?

PulteGroup

Sotherly Hotels

SOHO, DVA and PHM made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 19, 2023.

Best Value Stocks to Buy for July 19th

Apple

Activision Blizzard

American Express

Bank of America

ITOCHU Corp

Coca-Cola

Moody's

Mitsui & Co Ltd

The Oracle of Omaha has overseen a greater-than 4,200,000% return on Berkshire Hathaway's Class A shares (BRK.A) since becoming CEO. A top reason for Buffett's long-term outperformance is his penchant for portfolio concentration.

90% of Warren Buffett's $372 Billion Portfolio Is Invested in Only 14 Stocks

DENVER , July 13, 2023 /PRNewswire/ -- DaVita Inc. today announced that its Board of Directors appointed a new independent director, Wendy Schoppert, to join the Board, effective as of July 14, 2023. "We're pleased to welcome Wendy to DaVita's board," said Pam Arway, independent chair of the DaVita Inc. Board of Directors.

DaVita Announces Wendy Schoppert to Join its Board of Directors

DENVER , July 13, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Thursday, August 3rd, 2023, at 5:00 p.m. Eastern Time.

DaVita Inc. Schedules 2nd Quarter 2023 Investor Conference Call

American Airlines

Lately, it seems like the only thing that can stop the U.S. equity markets is a holiday early close. Heading into the 4th of July celebration, major stock indices are enjoying a festive 2023 thanks to 1) waning expectations of a long anticipated recession and 2) retreating inflation.

Wall Street Is Cautious on These 2 First Half Winners

Charter Communications

General Motors

Paramount Global

Plenty of investors are interested in the stocks that legendary investor Warren Buffett has selected for the Berkshire Hathaway (NYSE: BRK-A , NYSE: BRK-B ) equity portfolio. However, instead of buying every single stock in this category, you may want to focus mainly on the undervalued Buffett stocks instead.

The 7 Most Undervalued Buffett Stocks to Buy Now: June 2023

Amazon

Nu Holdings

StoneCo

According to current portfolio statistics, a Premium feature of GuruFocus, five stocks in Warren Buffett (Trades, Portfolio)'s first-quarter 13F equity portfolio that outperformed the Standard & Poor's 500 Index during the past six months include Nu Holdings Ltd. ( NU , Financial), Amazon.com Inc. ( AMZN , Financial), StoneCo Ltd.

Top-Performing Stocks of Warren Buffett's Berkshire as of June

Addus HomeCare

Amedisys

Chemed

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE, AMED and ADUS are well poised to gain.

4 Stocks to Hold in a Challenging Outpatient Home Health Industry

Investors remain optimistic about DaVita (DVA) due to the strength of its DaVita Kidney Care.

Here's Why You Should Retain DaVita (DVA) Stock for Now

iShares Select Dividend ETF

Floor & Decor Holdings

Liberty Media Corp-Liberty Formula One

Jefferies Financial Group Inc

Snowflake

SPDR Portfolio S&P 500 Growth ETF

Warren Buffett likes to brag about dividends from S&P 500 stocks. But this year he's scoring gains with no dividend Warren Buffett stocks.

Warren Buffett Is Making A Mint On 7 Stocks That Pay No Dividends

An interviewer once asked Warren Buffett about the worst trade he'd ever made

News for DaVita Stock (DVA)